Back

Hepcidin and cardiovascular events in patients with chronic kidney disease undergoing dialysis: a post-hoc analysis of the ASCEND-D trial

1 September 2025 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Risk scores in cardio-oncology Stratification, Prevention and Monitoring ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Yudai Fujimoto

Juntendo University Graduate School of Medicine, Tokyo (Japan)

6 More presentations in this session

Presentation thumbnail
Assessment of ESC risk stratification for cancer therapy-related cardiovascular toxicity in a real-world urban population
Doctor J. Arnold (Chicago, US)
Abstract Slides
Presentation thumbnail
Accurate and efficient cardio-oncology outpatient clinic summarization with open-source large language models for non-english text
Doctor J. Heemelaar (Leiderdorp, NL)
Abstract Slides
Presentation thumbnail
Systemic H-FABP, hs-cTnT, hs-CRP and Monocyte-to-Lymphocyte ratio were significantly reduced by sacubitril/valsartan in doxorubicin-treated preclinical models through NLRP3-mTOR-AKT pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
The new mechanism of apatinib in treating gastric cancer-related hypertension: dynamin-related protein 1-mediated pathological mitochondrial fission in endothelial cells
Doctor F. Si (Lanzhou, CN)
Abstract Slides
Presentation thumbnail
The diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune checkpoint inhibitor therapy.
Associate Professor C. Ayoub (Phoenix, US)
Abstract Slides

Access the full session

Session thumbnail
Risk scores in cardio-oncology

The Event

Event poster

ESC Congress 2025

1 September 2025 15:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources